medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2010, Number 1

<< Back Next >>

Rev Biomed 2010; 21 (1)

Evaluation of humoral response to Heberbiovac HB in haemodialysis patients from Havana City

Montalvo-Villalba MC, Delgado G, Díaz M, Bali A, Bello-Corredor M, Gutiérrez-Moreno A, Sariego-Frometa S, Rodríguez-Lay LÁ

Language: Spanish
References: 28
Page: 5-12
PDF size: 84.46 Kb.


ABSTRACT

Introduction. Patients under haemodialysis are an important risk group in the epidemiology of hepatitis B. Although, seroconversion rates induce by hepatitis B virus (HBV) vaccine are lower, its contribution to the substantial reduction of the morbidity and mortality by hepatitis B in haemodialysis (HD) centres is undoubted.
Objective. The aim of our study was to evaluate humoral response to Heberbiovac HB vaccine and associated factors related with anti-HBs levels in a group of patients in HD.
Materials and Methods. In this investigation, 152 patients from five HD units were studied, who gave their informed consent to participate in the serological and epidemiological survey. All patients were included in the immunization schedule recommended for Heberbiovac HB vaccine in HD: total dose administrated was 40µg at 0, 1, 5, 6, and 12 months, with annual reactivations. Serum samples were tested for HBsAg, total anti-HBc, and anti-HBs levels.
Results. Anti-HBs (≥10IU/L) were detected in 89.5% (136/152) patients in HD and mean geometric titers were 671.8 IU/L (CI 95%: 419.8-1085.7 IU/L). Protector titers of anti-HBs were statistically related with annual reactivations. Correlation with age, sex, and previous exposition to HBV was not found.
Conclusions. These findings demonstrate the immunogenicity of Heberviovac HB vaccine and the importance of following universal measure for controlling and preventing hepatitis B in HD centres, as there are patients within the hepatitis B immunization programme without anti-HBs seroconversion.


REFERENCES

  1. Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 2000; 18:57-67.

  2. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008; 8:235-47.

  3. Khamene ZR, Sepehrvand N. The status of immunity against the hepatitis B virus among vaccinated hemodialysis patients: a single center report from Iran. Saudi J Kidney Dis Transpl 2007; 18:547-50.

  4. Recommendations for Preventing Transmissión of Infections Among Chronic Hemodialysis Patients. MMWR Recommendation and Reports 2001; 50:1-43.

  5. Ramezani A, Eslamifar A, Banifazl M, Ahmadi F, Maziar S, Razeghi E, et al. Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract. 2009; 63:394-7.

  6. Barraclough KA, Wiggins KJ, Hawley CM, van Eps CL, Mudge DW, Johnson DW, et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis 2009; 54:95-103.

  7. Kong NC. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int. 2008; 73:856-62.

  8. Pedroso P, Díaz G, Rodríguez L. Aspectos inmunmogénicos de la vacuna de ADN recombinante cubana contra la Hepatitis B en adultos jóvenes. Comunicación breve. Avances en Biotecnología moderna 1997; 4:11-24.

  9. Rodríguez L, Balmaseda A, Bravo J, Trujillo J, Martínez L, Ochoa R, et al. Validation of a ultramicro ELISA for detecting antibodies against hepatitis B surface antigen. Rev Cubana Med Trop 1996; 48:45-9.

  10. Maisonneuve P, Agodoa L, Gellert R. Cancer in patient on dialysis for end-stage renal diseases: An international collaborative study. Lancet 1999; 354:93-9.

  11. Girndt M, Kőhler H. Hepatitis B virus infection in hemodialysis patients. Semin Nephrol 2002; 22:340-50.

  12. Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick KK, Combe C, Saito A, et al. Pattern of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS Kidney. Kidney Int 2003; 63:2222-29.

  13. González-Griego M, Pentón E, Delgado G, Pérez Oliva J, Izquierdo M, García G, et al. Impact of an anti-hepatitis B virus (HBV) immunization program in patients undergoing dialysis in Havana, Cuba. Invest Clin 2000; 41:237-44.

  14. Rodríguez L, Ustariz C, Corredor M, Gutiérrez A, Avila O, Delgado G. Immunogenicity of the Cuban anti-hepatitis B recombinant DNA vaccine in patients with Hematological Malignancies. Biotecnología Aplicada 2006; 23:25-27.

  15. Bruguera M, Rodicio JL, Alcazar JM, Oliver A, Del Rio G, Esteban-Mur R. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990; 8(Suppl 1):47-9.

  16. Weinstein T, Chagnac A, Boaz M, Ori Y, Herman M, Zevin D, et al. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract 2004; 7:67-72.

  17. Vlassopoulos D. Recombinant Hepatitis B vaccination in renal failure patients. Cur Phar Biotech 2003; 4:141-51.

  18. Rajapurkar MM, Gang S, Dabhi M, Kulkarni PS. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure. J Nephrol 2007; 20:596-601.

  19. Kundy M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Opin Biol Ther 2008; 8:235-47.

  20. Verkade MA, van Druningen CJ, Op de Hoek CT, Weimar W, Betjes MG. Decreased antigen-specific T-cell proliferation by moDC among hepatitis B vaccine non-responders on haemodialysis. Clin Exp Med. 2007; 7:65-71.

  21. Caillat ZS, Gimenez JJ, Wambergue F. Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigens. Kidney Int 1998; 53:1626-30.

  22. Eardley KS, Jones HE, Osman H, Smith S. Efficacy of the accelerated hepatitis B vaccination schedule used in hemodialysis patients post-exposure to virus: a single-centre experience. Neph Dial Trans 2002; 17:1982-87.

  23. Chen CH, Hong CC, Leu ML, Chuang CY, Wu MS, Lai PC. Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection. Vaccine 1997; 15:1353-57.

  24. Peces R, De la Torre M; Alcazar R, Urra JM. Prospective analysis of the factor influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997; 29:239-45.

  25. Shatat, HZ, Kotkat, AM, Farghaly, AG, Farghaly AG. Immune response to hepatitis B vaccine in haemodialysis patients. J Egypt Public Health Assoc 2000; 75:257-75.

  26. Teles SA, Martins RM, Lopes CL, dos Santos MA, Souza KP, Yoshida CF. Immunogenicity of a recombinant hepatitis B vaccine (Euvax-B) in haemodialysis patients and staff. Eur J Epid 2001; 17:145-149.

  27. Tanriverdi F, Silveira LF, MacColl GS, Bouloux PM. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol 2003; 176:293-304.

  28. Tsouchnikas I, Dounousi E, Xanthopoulou K, Papakonstantinou S, Thomoglou V, Tsakiris D. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007; 68:228-34.




2020     |     www.medigraphic.com